News
Latest news and updates on the project.
March 2023
March 2023 – Newsletter
March 2023 Newsletter : More info
December 2022
December 2022 – Newsletter
December 2022 Newsletter: More info
September 2022
September 2022 – Newsletter
Sep 2022 Newsletter: More info
June 2022
June 2022 – Newsletter
June 2022 Newsletter : More info
August 2020
Eight Patients are now Enrolled in the ImmuoSABR Clinical Trial
Our trial is steadily progressing and we now have eight patients in three centres enrolled in the ImmunoSABR trial .
February 2020
First Patients Enrolled in ImmuoSABR Clinical Trial
Great news the first patients have been enrolled in the ImmunoSABRclinical Trial at NKI and AZM
June 2019
METC Approval
METC approval received for the centres in Maastricht, Amsterdam and Nijmegen
February 2019
Annual ImmunoSABR Meeting 2019
Partners Meeting held in Amsterdam reporting on the progress of the project.
December 2018
New ImmunoSABR Website Launched
A new website has been designed to provide an overview of the ImmunoSABR project, its progress and information to the general public, patients and potential patients
October 2018
Presentation – Brussels & Roma
Professor Philippe Lambin – Immunocytokines and Radiation at the Institut Bordet, Brussels. Unconventional immunotherapy and Radiation given in Roma at the yearly national course of radiation Oncology
September 2018
Presentation – Paris
Professor Philippe Lambin given in Paris at the Immunorad meeting immunocytokines and radiation
August 2018
Presentation – New York
Professor Philippe Lambin given in New York MSKCC on Immunocytokines and radiation
July 2018
Presentation – Liverpool UK
Professor Philippe Lambin on Immunocytokines and Radiation given in Liverpool UK at UK Radiological Congress and Radiation and Oncology Congress (UKRCO)
June 2018
Amendment EU, Periodic report, (Ready for) Submission
Protocol final, ICF and patient info final, Other documents for submission final, EU amendment Part A and B final, EU Technical Report part B final, CTA final and signed, Finalizing deliverables
New Data
New data with three tumour models form the M-lab of precision medicine showing that immunocytokines, used in ImmunoSABR, worked better than checkpoint inhibitors with radiation.
May 2018
New Participant
Presentation by Professor Philippe Lambin in Antwerpen on ImmunoSABR led to them becoming a participant
April 2018
Presentation – Barcelona
Presentation by Professor Philippe Lambin (The M-Lab of Precision medicine) given at the ESTRO meeting in Barcelona on novel immunotherapy radiotherapy strategies Presentation by Damienne Marcus (The M-Lab of Precision medicine) given at the ESTRO meeting in Barcelona in on immunocytokines and radiation
March 2018
Presentation – Utrecht
Presentation by Professor Philippe Lambin given at the NVRO-NVRB meeting in Utrecht in on immunocytokines and radiation
January 2018
CRO
Tender (Negometrix), Submissions, Safety reporting, Risk analysis, Local monitors (visits), Training partners, Trial master file
March 2017
Kick Off Meeting – Presentation
First presentation was given by Professor Philippe Lambin , Brussels Kick off meeting introducing ImmunoSABR for a broad audience.
January 2017
H2020 Grant
H2020 grant – We received an H2020 grant from the European Union that helps us to cover the financial part for this study. We are working with a number of hospitals and centres throughout the European Union and aim to encompass patients within the whole of the EU
STAY INFORMED ?
If you want to stay informed about ImmunoSABR project, please subscribe to our newsletter.
CONTACT
The D-Lab / Precision Medicine
P.O. Box 616,
6200 MD Maastricht, The Netherlands
FUNDING
This project has received funding from the European Union’s. Horizon 2020 research and innovation programme under grant agreement No 733008
